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The tremendous contribution of nanotechnology to the treatment and diagnosis of medical diseases has 
recently attracted the attention of anticancer researchers. Most of the new nanoparticle carriers have 
improved drug bioavailability and reduced the cytotoxic effects of the drugs. This article presents an 
overview of the recent advances of nanotechnology in cancer therapy. It covers the mechanisms of 
cellular uptake for anticancer drugs delivered in nanoscale systems by either active or passive targeting. 
The various nanoscale systems employed in drug delivery and their immense potential in diagnosis and 
imaging of cancerous tumors are also addressed.  
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INTRODUCTION 
 
Cancer is considered one of the most 
common causes of death all over the world 
[1]. In spite of the research advances in anti-
cancer therapy, higher mortality rates are still 
associated more with the adverse side effects 
of therapeutic intervention than the cancer 
itself [2]. In fact, most anti-cancer drugs are 
very hydrophobic and have poor 
bioavailability. Therefore, they reach the 
tumor tissue with poor specificity and dose-
limiting toxicity. Usually, anticancer drugs are 
administered to patients via oral or 
intravenous route. The disadvantages of oral 
administration of tablets or capsules is the 
resulting disorderly pharmacokinetics due to 
the exposure of these agents to the metabolic 
pathways of the body, which can result in 
larger than necessary doses being 
administered and further cause increased 
toxicity. On the other hand, the specificity of 
some conventional intravenous drugs is low; 
resulting in harmful effects to healthy tissues 
and are often more problematic.  
 
Recent studies have demonstrated that 
encapsulation of anti-cancer drugs in a 
nanodroplet system would help in improving 
their cellular uptake and reducing their 
cytotoxic side effects [3]. These 
nanoparticulate systems are created at an 
incredibly small scale between 1 and 400 nm. 
They have showed a great potential by 
serving as carriers for drugs, genes and 
imaging agents that would bind efficiently and 
selectively to specific targets on injured or 
neoplastic tissue. Nanocarriers may include 
liposomes, micelles, dendrimers and 
emulsification systems.   
 
CELLULAR UPTAKE OF NANO-SCALE 
MATERIALS 
 
The various mechanisms of intracellular 
uptake of nanoparticles can be by phagocytic 
cells, non-phagocytic cells or drug resistant 
cancer cells [4]. Nanomaterials with a lower 
size are preferable to those in the upper 
submicron and micron ranges to achieve 
longer-circulation half-lives with reduced 
uptake of mononuclear phagocyte system 
(MPS) and more efficient cellular uptake with 
increased internalization. In particular, the 
cellular uptake of drug nanocarriers by 
phagocytic cells depends on the size that 
should not exceed 200 nm, surface charge 
and molecular interactions that might 
influence both the uptake and subsequent 
clearance by the MPS cells. On the other 
hand, internalization of particles by non-
phagocytic cells such as tumor cells would 
happen if the particles sizes are even > 500 
nm. Internalization of nanomedicines into the 
target cells can occur via a diverse range of 
endocytic pathways including phagocytosis, 
macropinocytosis, clathrin-mediated endocy-
tosis, and non–clathrin-mediated, such as, 
caveolae-mediated endocytosis. Another 
proposed mechanism of the cellular uptake 
that recently has gained interest is 
overcoming drug resistance in cancer 
chemotherapy by using nano-scale delivery 
systems [5]. Major mechanisms that have 
been proposed include enhanced intracellular 
concentration of the drug by endocytosis, 
inhibition of multidrug resistance proteins by 
carrier component materials such as Pluronic 
block copolymers, adhesion of nanoparticles 
to the cell surface, promotion of other uptake 
mechanisms such as receptor-mediated 
cellular internalization, and increased drug 
concentrations at the vicinity of target cancer 
cells. Furthermore, both drug and inhibitors of 
multidrug resistance proteins can be 
incorporated into the same carriers for 
simultaneous delivery to the cancer cells. For 
example, doxorubicin and cyclosporine A, 
encapsulated in polyalkylcyanoacrylate 
nanoparticles have been discovered to 
reverse resistance synergistically [6]. 
 
ROLE OF NANOPARTICLE SYSTEMS IN 
DIAGNOSIS AND IMAGING  
 
The National Cancer Institute (NCI) has 
recognized the immense potential that 
nanotechnology holds for the cancer 
diagnosis and treatment [7]. A good example 
for the application of nanotechnology in 
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oncology is the   immunoassays that employ 
the nanoparticles as markers in detecting the 
presence of tumors. These nanoparticles, 
containing quantum dots and molecular 
beacons (MBs), are synthetic, stable 
inorganic fluorophore semiconductors and 
have narrow emission spectra with wide 
excitation range [8, 9]. The quantum dot-
conjugated probes can be used to measure 
the expression levels of several specific 
malignant tumor biomarkers and at the same 
time, provide valuable data for treatment. The 
MBs are hairpin-shaped oligonucleotides that 
act like switches. They undergo conforma-
tional changes and fluoresce when turned on. 
When used as probes, MBs have valuable 
applications in the nucleic acid and gene 
expression monitoring and as biosensors. 
They also have the potential to become very 
useful tools in genomics and proteomics as 
they enable real-time detection of protein–
RNA–DNA interaction with high sensitivity 
and specificity. Other diagnostic probes may 
include nanoshells, gold nanoparticles, 
paramagnetic nanoparticles and carbon 
nanotubes.  
 
ROLE OF NANOPARTICLE SYSTEMS IN 
DRUG DELIVERY 
 
The major aim of pharmaceutical research is 
the proper distribution of drugs and other 
therapeutic agents within the patient’s body 
and delivering of any drug at the right time in 
a safe and reproducible manner to a specific 
target at the required level [10]. Oral route is 
considered as one of the preferred methods 
for drug delivery due to its non-invasive 
feature. However, adequate peptide or 
protein drug delivery has not yet been 
attained via this route [11]. This is partly due 
to the acidic conditions of the stomach, the 
first-pass effect of the liver that diminishes 
the drug by the metabolic processes before it 
goes through the systemic circulation, and 
the resistance exerted by the intestine which 
alter, destroy, or reduce absorption of nearly 
all therapeutic agents and hence, reduce the 
drug bioavailability. Accordingly, engineered 
nanodevices and nanostructures systems 
can improve the stability, absorption, and 
therapeutic concentration of the drug within 
the target tissue, as well as permit 
reproducible and long-term release of the 
drug at the target site. In addition to reducing 
the frequency of drug administration and thus 
improving patient comfort, novel drug delivery 
systems would offer protection and improve 
the pharmacokinetics of easily degradable 
peptides and proteins, which often have short 
half-lives in vivo. 
 
Nanoconjugates can also surmount the draw 
backs of the conventional chemotherapy 
which is non-specific in killing rapidly dividing 
cells whether within the tumor or in the 
normal tissues [12]. Selective targeting of 
tumor tissue is possible with modern 
macromolecular nanodelivery systems that 
deliver high drug concentrations and maximal 
effects to tumor tissue and minimal drug 
concentrations and negligible side effects to 
healthy tissue. Polymers as platforms for 
delivering agents into tumor cells have 
increasingly gained importance because they 
are unaffected by the multidrug resistance, 
MDR, which is an effect produced by cancer 
cells to the multiple different distinct drugs. 
The MDR have minimal immunogenicity and 
are able to maintain effectiveness with each 
cycle of tumor treatment. General macro-
molecular targeting of tumor tissue is referred 
to as “passive”, whereas site-specific 
targeting of cell surface molecules and 
receptors is referred to as “active”. In the 
following sections, both targeting will be 




Passive targeting of injured tissue occurs due 
to extravasation of the nanocarriers at the 
diseased site where the microvasculature of 
tumor and inflamed tissue is leaky as shown 
in Figure 1. Tumor vascular leakiness is the 
result of increased angiogenesis and the 
presence of cytokines, bradykinin and other 
vasoactive factors that enhance permeability 
[13]. Tumor angiogenesis is characterized by 
vessels with irregular diameters and 
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branching, and tumors lacking defining 
structures of vasculature such as arterioles, 
capillaries, or venules. The majority of solid 
tumors exhibit a vascular pore cutoff size 
between 380 and 780 nm. Therefore elevated 
levels of bradykinin result in vasodilatation 
and enhance the extravasation of 
nanocarriers of a size much smaller than the 
cutoff pore diameter to the target tumor sites 
and their retention in tumors which is called 
the passive enhanced permeability retention 
effect [14]. Tumors lack an effective 
lymphatic drainage system to clear these 
extravasated substances. As a consequence, 
macromolecules and nanoparticles, that enter 
the tumor, will accumulate. By contrast, 
normal vasculature is impermeable to drug 
associated carriers larger than two to four 
nanometer compared to free unassociated 
drug molecules (Figure 1). This nanosize 
window offers the opportunity to increase 
drug accumulation and local concentration in 
target sites by extravasation, and significantly 
to reduce drug distribution and toxicity to 




Figure 1: The uptake of the anticancer drug by 
cancerous and normal cells via passive targeting.  
Active targeting 
 
Cancerous and inflamed tissues are not only 
having leaky vasculature but also over-
express some epitopes or receptors that can 
be used as targets. Accordingly, it can be 
actively targeted by nanoconjugated ligands 
via targeting these receptors. Ligands that 
specifically bind to surface epitopes or 
receptors usually couple to the surface of 
long circulating nanocarriers [15]. Various 
methods have been employed to couple 
ligands to the surface of the nanocarriers with 
reactive groups. These can be divided into 
covalent and noncovalent couplings. 
Common covalent coupling methods involve 
formation of a disulfide bond, cross-linking 
between two primary amines, reaction 
between a carboxylic acid and primary 
amine, reaction between maleimide and thiol, 
reaction between hydrazide and aldehyde, 
and reaction between a primary amine and 
free aldehyde. Non-covalent binding by 
physical association of targeting ligands to 
the nanocarrier surface has the advantage of 
eliminating the use of rigorous, destructive 
reaction agents. However, there are potential 
problems, such as low and weak binding, and 
the ligands may not be in the desired 
orientation after binding.  
 
Ligand-mediated active binding to sites and 
cellular uptake are particularly valuable to 
therapeutics that are not taken up easily by 
cells and require facilitation by fusion, 
endocytosis, or other processes to access 
their cellular active sites. An important 
consideration when selecting the type of 
targeting ligand is its immunogenicity. For 
example, whole antibodies that expose their 
constant regions on the liposomal surface are 
more susceptible to Fc-receptor-mediated 
phagocytosis by the mononuclear phagocyte 
system [16]. 
 
Active targeting nanocarriers have a number 
of advantages over targeting ligand-drug 
conjugates [17]. First, high concentrations of 
drug within the carrier can be delivered to the 
target cell when a ligand interacts with its 
receptor. Second, the ligand is associated 
   Anti-cancer drug                Nanocarrier 
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with the carrier, and the drug is not modified 
with the coupling of ligands. Third, ligand 
molecules can be attached to the nanocarrier 
to increase probability of binding to target 
cells, particularly for therapeutics of lower 
binding affinities. Fourth, active targeting 
enables more efficient distribution of the 
carriers in the tumor interstitium and reduces 
return of drug back to the circulation due to 
high intratumoral pressure. Last, but also 
important, is that when ligand is only attached 
to the carrier due to the small size of the 
conjugate, it can only extravasate at the 
disease site but not at normal vasculature 
and therefore, the ligand cannot interact with 
the target epitopes of normal tissues and 
show side effects. Thus, nanocarriers can 
play an important role in reducing the 
toxicities of the drug and targeting ligand. 
Accordingly, nanoconjugates can be 
designed for sustained release of drug, 
passive enhanced permeability retention 
effect-based targeting of macromolecules to 
tumor tissue,  ligand-based targeting of cell 
surface antigens and modules active in 
endosomal uptake and membrane disruption,  
drug release into the cytoplasm, and 
protection of drugs from enzymatic 
degradation.  
 
NANOPARTICLE PLATFORMS FOR 
ANTICANCER DRUG DELIVERY 
 
Nanoparticulate systems for drug delivery 
can be produced by two different methods. 
The first method of nanosuspension 
production involves the breaking down of 
bigger particles to nanosize using high-
pressure homogenization of drug 
suspensions in the presence of surfactants 
[18]. The second method involves 
crystallization that build the nanoparticles up 
from the supersaturated solution state, or 
solid nanoparticles which can further be sub-
classified according to their composition: 
mainly polymer-based, lipid-based, and 
ceramic-based materials, albumin 
nanoparticles and nanogels [19]. The types of 
nanocarrier systems covered in this review 
article (see Figure 2) include liposomes, 







Figure 2: Schematic presentation of some 
nanoparticle platforms used for drug delivery. 
 
Liposomes with their long history starting 
from the mid-1980s were the first products to 
be used as nanocarriers and are available in 
the market (Table 1 and Figure 2). 
Daunorubicin and vincristine are anticancer 
drugs that have been loaded in liposomes 
and clinically used with the commercial 
names such as Daunoxome and Onco TCS, 
respectively. Doxorubicin loaded in liposomes 
is commercially marketed as Mayocet, and 
while that loaded in polyethyleneglyol-
liposomes is branded Doxil [17]. The 
liposomes’s vesicle size plays a critical role in 
complement activation and mononuclear 
phagocyte systems clearance of liposomes 
[20]. Vesicles larger than 100 nm require 
additional strategies to prevent surface 
opsonization. Liposomal anthracyclines have 
achieved highly efficient drug encapsulation, 
resulting in significant anticancer activity with 
reduced cardiotoxicity, and include versions 
with greatly prolonged circulation such as 
liposomal daunorubicin and pegylated 
liposomal doxorubicin. Pegylated liposomal 
doxorubicin has shown substantial efficacy in 
breast cancer treatment as monotherapy and 
in combination with other chemotherapeutics.  
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are under the in 
vitro evaluation 
[31, 32, 33].  
 
Liposomes with Sialyl Lewis X (SLX) proved 
to work as imaging reagent and drug delivery 
agent for fluorescent markers, proteins and 
genes [21,22].  Some liposomes were 
produced by encapsulating perfluorocarbon 
nanoparticle to be utilized as an imaging 
contrast agent. When doxorubicin was 
encapsulated in the formulation of human 
epidermal growth factor receptor 2-specific 
antibody (ZHER2:342-Cys) conjugated 
thermosensitive liposome, its targeting and 
triggering potential for breast cancer 
treatment was improved [23].  
 
Oxaliplatin, an anticancer drug, was delivered 
sequentially in a cationic liposome coated 
with polyethylene glycol and revealed dual 
targeting to both endothelial cells and tumor 
cells in solid tumor [24].  Another example on 
the cationic liposomes is the trilysinoyl 
oleylamide -based liposomes which displayed 
the greatest delivery efficiency of the 
anticancer drug suberoylanilide hydroxamic 
acid with minimal cytotoxicity compared to 
the other oligolysine-based cationic lipid 
derivatives [25].   
 
Micelles are nanosized assemblies of 
amphiphilic block copolymers exhibiting a 
unique core-corona structure (Figure 2 and 
Table 1). The hydrophilic corona is important 
to stabilize the micelles in an aqueous 
environment whereas the hydrophobic core 
functions as a drug reservoir [26]. Nanosized 
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micelles have polarity gradients from the 
highly hydrated corona to the hydrophobic 
core, and are used for solubilization of both 
hydrophilic and hydrophobic drugs. The 
hydrophobic interactions are the predominant 
driving force in the assembly of the 
amphiphiles in the aqueous medium when 
their concentrations exceed the critical 
micelle concentration, which is defined as the 
concentration of surfactants above which 
micelles are spontaneously formed. Micellar 
drug delivery systems can be divided into 
four classes that share a similar molecular 
architecture, phospholipid micelles, Pluronic 
micelles, Poly (L-amino acid) micelles and 
Polyester micelles. The clinical assessments 
for using the micelles are still in the early 
stages (phase 1). Recent studies have 
showed that assembling human tumor 
necrosis factor (TNF)-related apoptosis-
inducing ligand (Apo2L/TRAIL) and 
doxorubicin (Dox, an anti-cancer drug) or 
paclitaxel with micellar nanoparticles from a 
biodegradable cationic copolymer P(MDS-co-
CES) showed great potential in cancer 
therapy as it induces cell death selectively in 
cancer cells with limited toxicity to normal 
tissues [27,28].  
 
Another subclass of the nanoparticle systems 
is the dendrimers (Figure 2 and Table 1), that 
have been extensively investigated and 
under preclinical assessments for delivering 
various anticancer drugs [29,30]. Drug 
molecules can be associated with dendrimers 
by either encapsulated in the void spaces of 
the dendrimer interior or conjugated on the 
surface of the dendrimer.   
 
The proper choice of dendrimer as a drug 
delivery system could improve the circulation 
half-life and hence, develop the enhanced 
permeation retention effect phenomena that 
result in increasing the efficacy of the drug. 
For example, doxorubicin is one of the 
anticancer drugs that was encapsulated in a 
2, 2-bis (hydroxymethyl) propanoic acid 
based dendritic scaffold by a hydrazone 
linkage. Its cytoxicity was reduced and its 
half-life has increased compared to the free 
drug [31].  Doxorubicin was also conjugated 
into the polyamidoamine (PAMAM) dendrimer 
and coated with superparamagnetic iron 
oxide (Fe3O4) nanoparticles through acid-
cleavable hydrazone bonds which would 
make this dendritic platform a good candidate 
for cancer diagnosis in vivo [32]. 
 
Cisplatin is another anticancer drug that was 
also incorporated into generation 3.5 PAMAM 
dendrimer conjugated through the sodium 
carboxylate surface giving a dendrimer–
platinate (dendrimer–Pt; 20–25 wt% 
platinum), which resulted in a fairly water 
soluble nanoformulation with the ability to 
release cisplatin slowly in vitro. It showed 
greater antitumor activity over free cisplatin 
when injected into mice bearing B16F10 
tumor cells [33]. The saccharide-terminated 
generation 3 PAMAM dendrimer conjugated 
to the drug methotrexate proved to have a 
great potential in specifically targeting and 
killing the folate receptor-expressing tumor 
cells [34].  
 
In an attempt to improve the bioavailability, 
efficacy and half-life of anticancer drugs, 
dendrimers were attached to polyethylene 
glycols (PEG) which shield the body’s 
immune system. A research study suggested 
that the proper design of the size and surface 
characteristics of PEGylated Polylysine 
dendrimers would determine the rout of the 
delivery system.  It demonstrated that if 
dendrimer size was increased by increasing 
the chain length of attached polyethylene 
glycol chains, a dramatic increase in 
absorption efficiency after subcutaneous 
injection could be achieved and transported 
into the lymphatic system. Conversely, a 
shorter PEG chain was shown to lead to 
rapid absorption into the blood [35]. 
Doxorubicin was conjugated into generation 5 
PEGylated polylysine dendrimers comprising 
an outer generation of L-lysine or succinimyl 
dipropyldiamine. When this conjugate was 
evaluated in rats bearing Walker 256 tumors, 
it revealed higher uptake into tumor tissue 
compared to control tissue such as muscle 
and heart [36].  
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Nanoscale systems also include 
emulsification systems that are still under 
preclinical investigations. They can 
incorporate drug compounds and modify their 
bioavailability, stability, and reduce their side 
effects (Figure 2 and Table 2). They are 
colloidal systems that consist of two or more 
immiscible liquids stabilized by surfactants 
which are chemical compounds with polar 
head and non-polar tail [37]. These 
dispersion systems might produce different 
structures with distinct morphologies and 
sizes range from 1 – 400 nm. They are 
mainly classified according to their 
differences in the composition, appearance, 
kinetic and thermodynamic stability into 
emulsions, microemulsions and nanoemul-
sions.  
 
The structure of the single-phase for 
emulsification systems produced is affected 
by the fraction of oil and water. The structure 
can be oil-in-water (o/w), water-in-oil (w/o) or 
bicontinuous. In each type, there is an 
interfacial surfactant monolayer separating 
the water and oil domains. The presence of 
o/w droplets is likely to be produced where 
the volume fraction of oil is low while the w/o 
droplets are formed at a lower fraction of 
water. In systems where the amounts of 
water and oil are similar, a bicontinuous 
structure may result. The existence of 
microdomains of different polarity within the 
same single-phase solution enables both 
water-soluble and oil-soluble materials to be 
solubilized. 
 
Table 2: Characteristics of emulsification systems and their current stage of development for 
use in cancer therapy 
 
Characteristic Emulsion Microemulsion Nanoemulsion 
Appearance Opaque Transparent Transparent to slightly 
opaque 
Size (nm) >200  1 -100  1 -100  
Advantages Require fewer 
amounts of 
surfactants (~ 5%) 
Spontaneously formed 
Thermodynamically 





and kinetically stable 
Require fewer 
amounts of 
surfactants (~ 5%) 
Disadvantages Thermodynamically 
unstable and thus do 
not form 
spontaneously  




exposure to power 






by dilution, heating or 
changing pH levels. 
 
Require input of 
energy and 
specialized equipment 
to be produced 
Clinical trials Preclinical stages for 
evaluating vinorelbine-
loaded lipid emulsion 
[38]. 
In vivo and in vitro 
evaluation for the 












[43, 44, 45].  
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Some anticancer drugs were recently 
formulated in emulsion systems and were 
preclinically assessed (Figure 2 and Table 2). 
For example, the anticancer drug, 
vinorelbine, proved to have equivalent 
efficacy and lower toxicity compared to the 
commercial product Navelbine(®) when 
loaded in lipid emulsion as observed in 
tumor-bearing nude mouse models 
inoculated with A549 human lung cancer, 
hepatoma solidity (Heps) G2 cancer and 
BCAP-37 human breast cancer cells [38]. 
Furthermore, epirubicin, an anticancer drug, 
was encapsulated in water-in-oil-in-water 
emulsion containing glucose solution as the 
inner aqueous phase, lipiodol which 
consisted of polyglycerol esters of 
polycondensed fatty acids of castor oil, as the 
oily phase, and physiological saline with 
polyoxyethylene 60 stearate. The resulted 
formula revealed an effective treatment for 
patients with recurrent hepatocellular 
carcinoma after surgical resection [39].  
The proper microemulsion delivery systems 
of some anticancer drugs have showed 
decreased cytotoxic effect and have 
improved the efficacy of the drug (Figure 2 
and Table 2).  The in vitro evaluation of 
mitomycin C loaded in microemulsion 
revealed safe effect when subjected unto 
Calu1 and A549 lung carcinoma cell lines 
[40]. Another promising study proved that an 
oil-in-water microemulsion containing 
cremophor EL, ethanol, propylene glycol and 
saline solution would be a good candidate as 
an intravenous delivery of diallyl trisulfide 
which is an oil-soluble sulfur compound that 
induces apoptosis in tumor cells [41]. Lipidol 
microemulsions with adriamycin anticancer 
drug in combination with the antioxidant 
diethyldithiocarbamate demonstrated a 
significant antitumor activity in vivo and 
higher liver adriamycin concentration as 
compared to free adriamycin, adriamycin 
liposome, and adriamycin microsphere 
groups [42].  
 
Anticancer drugs loaded in nanoemulsion 
systems have greater activity against cancer 
cells in comparison to other emulsification 
systems (Figure 2 and Table 2). This is due 
to the decreased particle size and zeta 
potential, production of a stable water 
dispersion, reduced polydispersity index, and 
greater stability of drug with the 
nanoemulsion. When the anticancer drug 
dacarbazine was loaded in a nanoemulsion 
formula containing ethanol, soybean oil, 
polysorbate 80 and deionized water, its 
efficacy compared with the suspension 
formula was increased, revealed by the 
reduction of the tumor size in epidermoid 
carcinoma xenograft mice. A nanoemulsion 
formulation of dacarbazine reduces tumor 
size in a xenograft mouse epidermoid 
carcinoma model compared to dacarbazine 
suspension [43]. Paclitaxel, formulated in a 
self assembling nanoemulsion containing 
cremophor EL and ethanol solution, have 
showed improved inhibition effect of cell 
proliferation in breast, colon and pancreatic 
cell lines compared to blank nanoemulsion 
[44]. Another recent study has encapsulated 
the paclitaxel in perfluorocarbon 
nanoemulsions and showed excellent 
therapeutic properties characterized by tumor 
regression and suppression of metastasis 




Nanoparticle systems have shown great 
potential and promising result in cancer 
treatment and imaging. However, the 
physicochemical properties of nanoscale 
systems still need further in-depth research. 
In addition, the in vivo and in vitro evaluation 
of the nanocarriers capsulation for the anti-
cancer drugs are still under investigations. 
Discoveries of new nanoscale systems that 
are biocompatible are still limited to specific 
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